Application of immunotherapy in relapsed/refractory B-cell acute lymphoblastic leukemia / 中国药房
China Pharmacy
; (12): 886-889, 2024.
Article
em Zh
| WPRIM
| ID: wpr-1013555
Biblioteca responsável:
WPRO
ABSTRACT
Immunotherapy, as an emerging treatment method, has been proven to improve the prognosis of patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) and has good application prospects. Immunotherapy, including chimeric antigen receptor T cell immunotherapy (CAR-T) and monoclonal antibodies, has shown great potential for application, and has been approved for marketing. This article summarizes the application of the above two therapies in the treatment of relapsed/ refractory B-ALL, and concludes that CAR-T is a kind of personalized immunotherapy, and the selection of ideal targets is an important part of its action. Currently, the ideal targets in clinical studies include CD19, CD22 and CD19/CD22. Monoclonal antibodies, including blinatumomab and inotuzumab ozogamicin, have shown superior therapeutic efficacy for relapsed/refractory B- ALL. Immunotherapy has shown superior therapeutic effects compared to conventional chemotherapy, expanding the selection of treatment options for relapsed/refractory B-ALL.
Texto completo:
1
Base de dados:
WPRIM
Idioma:
Zh
Revista:
China Pharmacy
Ano de publicação:
2024
Tipo de documento:
Article